Trusted Supply of Critical & Orphan Medicines, Worldwide!

Drug: Regorafenib
Brand: Regorafenib 40mg
Manufacturer /
TM Owner
Bayer
Origin: Germany

Regorafenib 40mg Tablet

Regorafenib contains Regorafenib, a targeted kinase inhibitor. It blocks specific enzymes that drive cancer cell growth and survival, offering a precision alternative to conventional chemotherapy. It is used in the treatment of a range of cancers. It is supplied as a tablet (40mg). Available on prescription, it forms part of modern, guideline-driven care.
Strength: 40mg
Pack Size: 84s
Storage: 20°C to 25°C
Form: Tablet

+91 900 500 9556

Global Shipping : Reliable Global Distribution Network

Express Delivery : Priority Shipping for Every Order

Secure Payments : Trusted Payment Protection System

Disclaimer
All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the 'Manufacturer/ TM Owner' section in compliance with statutory requirements. Read More

Secure Handling

24/7 Worldwide Support

Global Access

Worldwide Access to Health

Cold-Chain Expert

Excellence in Cold-Chain

Trusted Supply

Certified Medical Supply

Indications & Clinical Uses

  • This sheet entry is a generic/molecule-name row: 'Regorafenib' is the active substance, and the approved brand under which it is sold is Stivarga (Bayer).
  • Stivarga (regorafenib) 40 mg tablets are an oral multikinase inhibitor approved for adults with metastatic colorectal cancer previously treated with standard chemotherapy, targeted anti-VEGF and, if appropriate, anti-EGFR therapy; for locally advanced, unresectable or metastatic gastrointestinal stromal tumours (GIST) previously treated with imatinib and sunitinib; and for hepatocellular carcinoma previously treated with sorafenib.
  • The standard dose is 160 mg (four 40 mg tablets) taken once daily for the first 21 days of each 28-day cycle, with a low-fat meal containing fewer than 600 calories and less than 30% fat, since a high-fat meal increases absorption unpredictably.
  • Stivarga is a specialist oncology medicine started and monitored by a cancer specialist; it is not interchangeable with other kinase inhibitors used in the same cancers.

Side Effects

  • Stivarga carries a boxed warning: severe and sometimes fatal hepatotoxicity (liver injury) has occurred in clinical trials, so liver function tests are checked before starting and regularly during treatment, and the dose is interrupted, then reduced or stopped, if liver injury develops.
  • Very common side effects include fatigue, loss of appetite, hand-foot skin reaction (redness, pain, peeling of the palms and soles), diarrhoea, mouth sores, high blood pressure, weight loss, infection, voice changes and rash.
  • Seek urgent medical attention for yellowing of the skin or eyes, dark urine, severe abdominal pain, signs of bleeding, severe diarrhoea or dehydration, chest pain, sudden weakness or confusion, or a wound that will not heal, since Stivarga can also cause serious bleeding, high blood pressure, heart problems and impaired wound healing.

Precautions & Warnings

  • Liver function is checked before starting Stivarga and at least every two weeks for the first two months, then monthly, because of the boxed hepatotoxicity warning; treatment is stopped permanently for severe liver injury.
  • Blood pressure is checked weekly for the first six weeks and regularly afterwards, since Stivarga commonly causes hypertension.
  • Stivarga is stopped at least 2 weeks before elective surgery because of impaired wound healing and is not restarted until the wound has adequately healed.
  • It can cause severe bleeding and should be stopped permanently for serious bleeds; it is used cautiously in people at high cardiovascular risk because of arterial thromboembolic events reported in trials.
  • Effective contraception is required during treatment and for a period after the last dose for both women and men, since Stivarga can harm an unborn baby; it is not used in pregnancy or while breastfeeding.

Avoid Interactions

  • Tell your healthcare provider about all medicines and supplements, since Stivarga is broken down by the liver enzyme CYP3A4 and by UGT1A9.
  • Strong CYP3A4 inhibitors, such as clarithromycin, itraconazole, ketoconazole and grapefruit or grapefruit juice, raise regorafenib levels and should be avoided; strong CYP3A4 inducers, such as rifampin, phenytoin, carbamazepine and St John's Wort, lower its levels and reduce effectiveness and should also be avoided.
  • Stivarga increases exposure to some other drugs metabolised by CYP2C8, such as certain statins, and to warfarin, which may need closer INR monitoring for bleeding.
  • It should be taken with a low-fat meal, as a high-fat meal increases drug absorption unpredictably.
  • Discuss any planned vaccination with your oncology team, given the effect on wound healing and general immune status.

References

Frequently Asked Questions

Regorafenib, sold under the brand name Stivarga, is an oral cancer medicine for adults with previously treated metastatic colorectal cancer, gastrointestinal stromal tumours (GIST), or hepatocellular carcinoma after sorafenib. 'Regorafenib' is the active ingredient name; Stivarga is the approved brand on the pack.

Simple Working Process

We have simplified the online drug ordering process into 4 easy steps to ensure
a safe, secure, and hassle-free experience for our customers.


Order Online

Place your order online and upload prescription in minutes with ease.



Order Confirmation

We verify your prescription and confirm your order quickly and securely.



Prescription Review

Reviewed by licensed pharmacists. Carefully processed and validated.

R

Receive Medicines

Approved order delivered fast, easy, and right to your doorstep or nearby Airport.



Global Standards. Trusted Care.

Trusted & Reliable – Your Partner in Global Distribution.

We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.